
Jens Cosedis Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2114310/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm, 2017, 14, e275-e444.	0.7	1,671
2	Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. New England Journal of Medicine, 2016, 375, 1221-1230.	27.0	1,350
3	HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. Heart Rhythm, 2014, 11, 1304-1323.	0.7	1,077
4	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace, 2018, 20, e1-e160.	1.7	767
5	Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. European Heart Journal, 2014, 35, 1186-1194.	2.2	653
6	Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation. New England Journal of Medicine, 2012, 367, 1587-1595.	27.0	574
7	A randomized comparison ofatrial and dual-chamber pacing in177 consecutive patients with sick sinus syndrome. Journal of the American College of Cardiology, 2003, 42, 614-623.	2.8	467
8	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace, 2018, 20, 157-208.	1.7	375
9	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	1.7	370
10	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Journal of Arrhythmia, 2017, 33, 369-409.	1.2	348
11	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. American Heart Journal, 2017, 189, 137-145.	2.7	258
12	2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS. Europace, 2018, 20, 1217-1217.	1.7	243
13	A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. European Heart Journal, 2011, 32, 686-696.	2.2	241
14	A Decade of Information on the Use of Cardiac Implantable Electronic Devices and Interventional Electrophysiological Procedures in the European Society of Cardiology Countries: 2017 Report from the European Heart Rhythm Association. Europace, 2017, 19, ii1-ii90.	1.7	216
15	diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	1.7	216
16	Association for Cardio. Europace, 2020, 22, 515-549. Heart Failure and Echocardiographic Changes During Long-term Follow-up of Patients With Sick Sinus Syndrome Randomized to Single-Chamber Atrial or Ventricular Pacing. Circulation, 1998, 97, 987-995.	1.6	210
17	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal, 2018, 39, 2942-2955.	2.2	181
18	Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace, 2015, 17, 370-378,	1.7	154

#	Article	IF	CITATIONS
19	His or para-His pacing preserves left ventricular function in atrioventricular block: a double-blind, randomized, crossover study. Europace, 2014, 16, 1189-1196.	1.7	144
20	Incidence of device-related infection in 97Â750 patients: clinical data from the complete Danish device-cohort (1982–2018). European Heart Journal, 2019, 40, 1862-1869.	2.2	136
21	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Heart Rhythm, 2017, 14, e445-e494.	0.7	135
22	Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. Circulation, 2017, 136, 1772-1780.	1.6	134
23	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 27-50. European Heart Rhythm Association (EHRA) international consensus document on how to prevent,	1.7	121
24	diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	2.2	120
25	Association for Cardi. European Heart Journal, 2020, 41, 2012-2032. Atrioventricular Conduction During Long-Term Follow-Up of Patients With Sick Sinus Syndrome. Circulation, 1998, 98, 1315-1321. European Heart Rhythm Association (EHRA) international consensus document on how to prevent,	1.6	112
26	diagnose, and treat cardiac implantable electronic device infections—endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European	1.4	111
27	Association for Cardio. European Journal of Cardio-thoracic Surgery, 2020, 57, e1-e31. Multimodality imagingâ€guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial. European Journal of Heart Failure, 2016, 18, 1365-1374.	7.1	103
28	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	7.1	101
29	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	1.7	95
30	EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace, 2021, 23, 983-1008.	1.7	92
31	Pneumothorax in cardiac pacing: a population-based cohort study of 28 860 Danish patients. Europace, 2012, 14, 1132-1138.	1.7	84
32	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Journal of Interventional Cardiac Electrophysiology, 2017, 50, 1-55.	1.3	83
33	The â€~10 commandments' for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 4295-4295.	2.2	79
34	Infected cardiac-implantable electronic devices: prevention, diagnosis, and treatment. European Heart Journal, 2015, 36, 2484-2490.	2.2	76
35	Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial. Heart, 2017, 103, 368-376.	2.9	74
36	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace, 2020, 22, 1147-1148.	1.7	62

#	Article	IF	CITATIONS
37	Atrial fibrillation in patients with sick sinus syndrome: the association with PQ-interval and percentage of ventricular pacing. Europace, 2012, 14, 682-689.	1.7	60
38	Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. Heart Rhythm, 2015, 12, 2368-2375.	0.7	60
39	Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association. Europace, 2019, 21, 1270-1279.	1.7	49
40	30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death. International Journal of Cardiology, 2016, 225, 30-36.	1.7	45
41	Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for AtrialÂFibrillation. JACC: Clinical Electrophysiology, 2016, 2, 170-180.	3.2	44
42	Long-term outcome of ablative therapy of post-operative atrial tachyarrhythmias in patients with tetralogy of Fallot: a European multi-centre study. Europace, 2012, 14, 522-527.	1.7	43
43	Left and right ventricular lead positions are imprecisely determined by fluoroscopy in cardiac resynchronization therapy: a comparison with cardiac computed tomography. Europace, 2014, 16, 1334-1341.	1.7	43
44	The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace, 2015, 17, 48-55.	1.7	42
45	The impact of coâ€morbidity burden on appropriate implantable cardioverter defibrillator therapy and allâ€cause mortality: insight from Danish nationwide clinical registers. European Journal of Heart Failure, 2017, 19, 377-386.	7.1	42
46	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Journal of Arrhythmia, 2020, 36, 553-607.	1.2	40
47	Very long term followâ€up of cardiac resynchronization therapy: Clinical outcome and predictors of mortality. European Journal of Heart Failure, 2008, 10, 796-801.	7.1	37
48	Managed ventricular pacing compared with conventional dual-chamber pacing for elective replacement in chronically paced patients: Results of the Prefer for Elective Replacement Managed Ventricular Pacing randomized study. Heart Rhythm, 2014, 11, 992-1000.	0.7	36
49	Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: On-treatment analysis of the randomized controlled MANTRA-PAF trial. International Journal of Cardiology, 2015, 198, 108-114.	1.7	33
50	Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace, 2017, 19, 132-138.	1.7	32
51	Should the Presence or Extent of Coronary Artery Disease be Quantified in the CHA2DS2-VASc Score in Atrial Fibrillation? A Report from the Western Denmark Heart Registry. Thrombosis and Haemostasis, 2018, 118, 2162-2170.	3.4	32
52	Electrically vs. imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial. Europace, 2019, 21, 1369-1377.	1.7	32
53	Remote monitoring of cardiac implanted electronic devices: legal requirements and ethical principles - ESC Regulatory Affairs Committee/EHRA joint task force report. Europace, 2020, 22, 1742-1758.	1.7	32
54	Radiofrequency ablation of accessory pathways in patients with the Wolff-Parkinson-White syndrome: the long-term mortality and risk of atrial fibrillation. Europace, 2015, 17, 117-122.	1.7	31

#	Article	IF	CITATIONS
55	Thirteen-year nationwide trends in use of implantable cardioverter-defibrillators and subsequent long-term survival. Heart Rhythm, 2015, 12, 2018-2027.	0.7	31
56	Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH). American Heart Journal, 2016, 179, 136-141.	2.7	29
57	Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit. JACC: Heart Failure, 2019, 7, 717-724.	4.1	29
58	Regional myocardial perfusion during chronic biventricular pacing and after acute change of the pacing mode in patients with congestive heart failure and bundle branch block treated with an atrioventricular sequential biventricular pacemaker. European Journal of Heart Failure, 2003, 5, 179-186.	7.1	28
59	Radiofrequency ablation lesions in low-, intermediate-, and normal-voltage myocardium: an in vivo study in a porcine heart model. Europace, 2019, 21, 1919-1927.	1.7	28
60	Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With) Tj ETQq0 0 0	rgBT /Ove	erlock 10 Tf 50
61	Management of Cardiac Electronic Device Infections: Challenges and Outcomes. Arrhythmia and Electrophysiology Review, 2016, 5, 183.	2.4	27
62	Association between ventricular pacing and persistent atrial fibrillation in patients indicated to elective pacemaker replacement: Results of the Prefer for Elective Replacement MVP (PreFER MVP) randomized study. Heart Rhythm, 2015, 12, 2239-2246.	0.7	26
63	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. Europace, 2020, 22, 1026-1035.	1.7	26
64	Aetiologies and temporal trends of atrioventricular block in young patients: a 20-year nationwide study. Europace, 2019, 21, 1710-1716.	1.7	25
65	European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). Europace, 2018, 20, 895-896.	1.7	24
66	Long-term outcomes in young patients with atrioventricular block of unknown aetiology. European Heart Journal, 2021, 42, 2060-2068.	2.2	24
67	Coronary artery disease and risk of adverse cardiac events and stroke. European Journal of Clinical Investigation, 2017, 47, 819-828.	3.4	23
68	Multisize Electrodes for SubstrateÂldentification in IschemicÂCardiomyopathy. JACC: Clinical Electrophysiology, 2019, 5, 1130-1140.	3.2	23
69	Implant-based multi-parameter telemonitoring of patients with heart failure and a defibrillator with vs. without cardiac resynchronization therapy option: a subanalysis of the IN-TIME trial. Clinical Research in Cardiology, 2019, 108, 1117-1127.	3.3	23
70	Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy. Europace, 2016, 18, 413-419.	1.7	22
71	The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome. European Heart Journal, 2020, 41, 2003-2011.	2.2	22
72	Single lead atrial vs. dual chamber pacing in sick sinus syndrome: extended register-based follow-up in the DANPACE trial. Europace, 2017, 19, 1981-1987.	1.7	21

#	Article	IF	CITATIONS
73	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. Europace, 2020, 22, 1337-1344.	1.7	21
74	Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 182-188.	3.0	20
75	Single-coil and dual-coil defibrillator leads and association with clinical outcomes in a complete Danish nationwide ICD cohort. Heart Rhythm, 2016, 13, 706-712.	0.7	20
76	Nationwide experience of catecholaminergic polymorphic ventricular tachycardia caused by RyR2 mutations. Heart, 2017, 103, 901-909.	2.9	20
77	European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace, 2022, 24, 165-172.	1.7	20
78	QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy. CNS Spectrums, 2018, 23, 278-283.	1.2	18
79	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace, 2021, 23, 1324-1342.	1.7	18
80	Outcomes of conduction system pacing compared to right ventricular pacing as a primary strategy for treating bradyarrhythmia: systematic review and meta-analysis. Clinical Research in Cardiology, 2022, 111, 1198-1209.	3.3	18
81	New onset anxiety and depression in patients with an implantable cardioverter defibrillator during 24Âmonths of follow-up (data from the national DEFIB-WOMEN study). General Hospital Psychiatry, 2021, 72, 59-65.	2.4	18
82	Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation. Heart, 2020, 106, 1919-1926.	2.9	17
83	HRS Clinical Document Development Methodology Manual and Policies: Executive summary. Heart Rhythm, 2017, 14, e495-e500.	0.7	16
84	Long-term outcomes in a randomized controlled trial of multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy. Europace, 2022, 24, 828-834.	1.7	16
85	Higher burden of supraventricular ectopic complexes early after catheter ablation for atrial fibrillation is associated with increased risk of recurrent atrial fibrillation. Europace, 2018, 20, 50-57.	1.7	15
86	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Heart Rhythm, 2020, 17, e269-e316.	0.7	15
87	Longer inter-lead electrical delay is associated with response to cardiac resynchronization therapy in patients with presumed optimal left ventricular lead position. Europace, 2018, 20, 1630-1637.	1.7	14
88	Recurrent atrial flutter ablation and incidence of atrial fibrillation ablation after first-time ablation for typical atrial flutter: A nation-wide Danish cohort study. International Journal of Cardiology, 2020, 298, 44-51.	1.7	14
89	Avoiding implant complications in cardiac implantable electronic devices: what works?. Europace, 2021, 23, 163-173.	1.7	14
90	Prospective nationwide fluoroscopic and electrical longitudinal follow-up of recalled Riata defibrillator leads in Denmark. Heart Rhythm, 2014, 11, 2141-2147.	0.7	13

#	Article	IF	CITATIONS
91	An anterior left ventricular lead position is associated with increased mortality and non-response in cardiac resynchronization therapy. International Journal of Cardiology, 2016, 222, 157-162.	1.7	13
92	Remote monitoring and clinical outcomes: details on information flow and workflow in the IN-TIME study. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 136-144.	4.0	13
93	Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical Research in Cardiology, 2020, 109, 638-645.	3.3	12
94	Anxiety and depression symptoms in Danish patients with an implantable cardioverter-defibrillator: prevalence and association with indication and sex up to 2 years of follow-up (data from the national) Tj ETQq0 () 01r. g BT /C	ovenbock 10 T
95	MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. Circulation, 2022, 145, 906-915.	1.6	12
96	Study Design and Cohort Description of DEFIBâ€₩OMEN: A National Danish Study in Patients with an ICD. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1261-1268.	1.2	11
97	Atrial fibrillation detected by external loop recording for seven days or two-day simultaneous Holter recording: A comparison in patients with ischemic stroke or transient ischemic attack. Journal of Electrocardiology, 2017, 50, 287-293.	0.9	11
98	A randomized trial of contact force in atrial flutter ablation. Europace, 2020, 22, 947-955.	1.7	11
99	His Bundle Pacing: Techniques and Outcomes. Current Cardiology Reports, 2016, 18, 76.	2.9	10
100	Association between Type D personality and outcomes in patients with non-ischemic heart failure. Quality of Life Research, 2019, 28, 2901-2908.	3.1	10
101	External continuous ECG versus loop recording for atrial fibrillation detection in patients who had a stroke. Heart, 2019, 105, 848-854.	2.9	10
102	The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. Europace, 2019, 21, 900-908.	1.7	10
103	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	1.2	10
104	Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trial. Europace, 2021, 23, 587-595.	1.7	10
105	Implantable cardioverter-defibrillators and subsequent cancer risk: a nationwide population-based cohort study. Europace, 2015, 17, 902-908.	1.7	9
106	Is the knowledge of contact force beneficial in pulmonary vein antrum isolation?. Scandinavian Cardiovascular Journal, 2017, 51, 129-137.	1.2	9
107	Time until diagnosis of clinical events with different remote monitoring systems in implantable cardioverter-defibrillator patients. Heart Rhythm, 2018, 15, 1648-1654.	0.7	9
108	The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure. Europace, 2019, 21, 1203-1210.	1.7	9

#	Article	IF	CITATIONS
109	Incidence of appropriate implantable cardioverter-defibrillator therapy and mortality after implantable cardioverter-defibrillator generator replacement: results from a real-world nationwide cohort. Europace, 2019, 21, 1211-1219.	1.7	9
110	The paced electrocardiogram cannot be used to identify left and right ventricular pacing sites in cardiac resynchronization therapy: validation by cardiac computed tomography. Europace, 2015, 17, 432-438.	1.7	8
111	Effectiveness of a comprehensive interactive eHealth intervention on patient-reported and clinical outcomes in patients with an implantable cardioverter defibrillator [ACQUIRE-ICD trial]: study protocol of a national Danish randomised controlled trial. BMC Cardiovascular Disorders, 2018, 18, 136.	1.7	8
112	Outcome after catheter ablation for left atrial flutter. Scandinavian Cardiovascular Journal, 2019, 53, 133-140.	1.2	8
113	Microbiological diagnosis in cardiac implantable electronic device infections detected by sonication and next-generation sequencing. Heart Rhythm, 2022, 19, 901-908.	0.7	8
114	The patient perspective on the Riata defibrillator lead advisory: A Danish nationwide study. Heart Rhythm, 2014, 11, 2148-2155.	0.7	7
115	Refusing Implantable Cardioverter Defibrillator (ICD) Replacement in Elderly Persons-The Same as Giving Up Life: A Qualitative Study. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1275-1286.	1.2	7
116	Ankyrin-2 variants associated with idiopathic ventricular fibrillation storm in patients with intermittent early repolarization pattern. HeartRhythm Case Reports, 2015, 1, 337-341.	0.4	7
117	Retrieval of Medtronic Micra Transcatheter Pacing System after tether removal. Europace, 2016, 18, 1202-1202.	1.7	7
118	ICD Implantation in Patients with Nonischemic Heart Failure. New England Journal of Medicine, 2017, 376, 89-92.	27.0	7
119	Association between right ventricular lead position and clinical outcomes in patients with cardiac resynchronization therapy. Europace, 2018, 20, 629-635.	1.7	7
120	Targeted next generation sequencing in a young population with suspected inherited malignant cardiac arrhythmias. European Journal of Human Genetics, 2018, 26, 303-313.	2.8	7
121	Electrically guided versus imaging-guided implant of the left ventricular lead in cardiac resynchronization therapy: a study protocol for a double-blinded randomized controlled clinical trial (ElectroCRT). Trials, 2018, 19, 600.	1.6	7
122	Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study. Europace, 2019, 21, 465-474.	1.7	7
123	Reproducibility of measuring QRS duration and implications for optimization of interventricular pacing delay in cardiac resynchronization therapy. Annals of Noninvasive Electrocardiology, 2019, 24, e12621.	1.1	7
124	Quality of life and the associated risk of all-cause mortality in nonischemic heart failure. International Journal of Cardiology, 2020, 305, 92-98.	1.7	7
125	Discontinuation of oral anticoagulation and risk of stroke and death after ablation for typical atrial flutter: A nation-wide Danish cohort study. International Journal of Cardiology, 2021, 333, 110-116.	1.7	7
126	Pacing mode selection in patients with sick sinus syndrome. Danish Medical Bulletin, 2007, 54, 1-17.	0.3	7

#	Article	IF	CITATIONS
127	Pacing in sinus node disease to prevent atrial fibrillation. Expert Review of Cardiovascular Therapy, 2012, 10, 851-858.	1.5	6
128	Health economic evaluation of single-lead atrial pacing vs. dual-chamber pacing in sick sinus syndrome. Europace, 2014, 16, 866-872.	1.7	6
129	Antiarrhythmic medication is superior to catheter ablation in suppressing supraventricular ectopic complexes in patients with atrial fibrillation. International Journal of Cardiology, 2017, 244, 186-191.	1.7	6
130	The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers. Europace, 2018, 20, 301-307.	1.7	6
131	The impact of supraventricular ectopic complexes in different age groups and risk of recurrent atrial fibrillation after antiarrhythmic medication or catheter ablation. International Journal of Cardiology, 2018, 250, 122-127.	1.7	6
132	Hidden burden of arrhythmias in patients with small atrial septal defects: a nationwide study. Open Heart, 2019, 6, e001056.	2.3	6
133	Self-reported health status and the associated risk of mortality in heart failure: The DANISH trial. Journal of Psychosomatic Research, 2020, 137, 110220.	2.6	6
134	Long-term follow-up of abandoned transvenous defibrillator leads: a nationwide cohort study. Europace, 2020, 22, 1097-1102.	1.7	6
135	Temporal Incidence of Appropriate and Inappropriate Therapy and Mortality in Secondary Prevention ICD Patients by Cardiac Diagnosis. JACC: Clinical Electrophysiology, 2021, 7, 781-792.	3.2	6
136	Rate of device-related infections using an antibacterial envelope in patients undergoing cardiac resynchronization therapy reoperations. Europace, 2022, 24, 421-429.	1.7	6
137	Risk of Cardiac Implantable Electronic Device Malfunctioning During Pencil Beam Proton Scanning in an In Vitro Setting. International Journal of Radiation Oncology Biology Physics, 2021, 111, 186-195.	0.8	6
138	Does catheter ablation reduce mortality and stroke in patients with atrial fibrillation? Patient selection or causality?. European Heart Journal, 2016, 37, 2488-2489.	2.2	5
139	Venous thromboembolism in patients with implantable cardioverter-defibrillators. Europace, 2016, 19, euw124.	1.7	5
140	Beta-Blocker Therapy Early After Myocardial Infarction: A Comparison Between Medication at Hospital Discharge and Subsequent Pharmacy-Dispensed Medication. Drugs - Real World Outcomes, 2016, 3, 279-288.	1.6	5
141	Left atrial size and function as assessed by computed tomography in cardiac resynchronization therapy: Association to echocardiographic and clinical outcome. International Journal of Cardiovascular Imaging, 2017, 33, 917-925.	1.5	5
142	Predicting stroke in patients without atrial fibrillation. European Journal of Clinical Investigation, 2019, 49, e13103.	3.4	5
143	Appropriate use of genetics in a young patient with atrioventricular block and family history of sudden cardiac death. HeartRhythm Case Reports, 2019, 5, 169-172.	0.4	5
144	Non-infective left ventricular lead complications requiring re-intervention following cardiac resynchronization therapy: prevalence, causes and outcomes. Journal of Interventional Cardiac Electrophysiology, 2022, 63, 69-75.	1.3	5

#	Article	IF	CITATIONS
145	Driving following defibrillator implantation: a nationwide register-linked survey study. European Heart Journal, 2021, 42, 3529-3537.	2.2	5
146	Periodic Repolarization Dynamics Identifies ICD Responders in Nonischemic Cardiomyopathy: A DANISH Substudy. Circulation, 2022, 145, 754-764.	1.6	5
147	Left ventricular regional remodeling and lead position during cardiac resynchronization therapy. Heart Rhythm, 2018, 15, 1542-1549.	0.7	4
148	Association between implantable cardioverter-defibrillator therapy and different lead positions in patients with cardiac resynchronization therapy. Europace, 2018, 20, e133-e139.	1.7	4
149	Current status of interventional cardiac electrophysiology training in ESC member countries: an EHRA Young EP Report. Europace, 2019, 21, 522-524.	1.7	4
150	Use of a snare to aid implanting leadless pacemaker in a patient with severely dilated atria. Europace, 2021, 23, 246-246.	1.7	4
151	NT-proBNP and ICD in Nonischemic Systolic HeartÂFailure. JACC: Heart Failure, 2022, 10, 161-171.	4.1	4
152	To burn or to freeze: a burning question yet to be resolved. European Heart Journal, 2016, 37, 2866-2868.	2.2	3
153	Premature atrial complexes in an ischemic stroke population and risk of recurrent stroke: a systematic review. Expert Review of Cardiovascular Therapy, 2017, 15, 447-455.	1.5	3
154	Safety and effectiveness of a 6â€French MRI conditional pacemaker lead: The INGEVITY TM clinical investigation study results. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1121-1128.	1.2	3
155	Implantable cardioverter-defibrillator therapy and device-related complications in young patients with inherited cardiomyopathies or channelopathies: a 17-year cohort study. Europace, 2018, 20, 1849-1855.	1.7	3
156	Recurrence after pulmonary vein isolation is associated with low contact force. Scandinavian Cardiovascular Journal, 2018, 52, 28-33.	1.2	3
157	Significant regional variation in use of implantable cardioverter-defibrillators in Denmark. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 352-360.	4.0	3
158	Burden of Premature Atrial Complexes and Risk of Recurrent Stroke and Death in Patients with Mild to Moderate Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104490.	1.6	3
159	Contemporary Patients With Congenital Heart Disease. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009695.	4.8	3
160	Electroanatomical mapping– and CT scan image integration–guided pacing lead implantation: A case series and review of the recent literature. Heart Rhythm O2, 2020, 1, 341-350.	1.7	3
161	Familial risk of atrioventricular block in first-degree relatives. Heart, 2022, 108, 1194-1199.	2.9	3
162	Two case reports of transcatheter valve-in-valve implantation of Sapien 3 and MyVal in degenerated biological tricuspid prosthesis valves. European Heart Journal - Case Reports, 2022, 6, ytac131.	0.6	3

#	Article	IF	CITATIONS
163	Failure of ICD therapy in lethal arrhythmogenic right ventricular cardiomyopathy type 5 caused by the TMEM43 p.Ser358Leu mutation. HeartRhythm Case Reports, 2016, 2, 217-222.	0.4	2
164	Repeated molecular genetic analysis in Brugada syndrome revealed a novel disease-associated large deletion in the SCN5A gene. HeartRhythm Case Reports, 2016, 2, 261-264.	0.4	2
165	Normativity under change. Nursing Ethics, 2016, 23, 328-338.	3.4	2
166	Longevity of implantable cardioverter-defibrillators: still a long way to go. Europace, 2016, 18, 1285-1286.	1.7	2
167	Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure. Circulation: Heart Failure, 2019, 12, e006022.	3.9	2
168	Left Atrial Function Determined by Cardiac Computed Tomography Predicts Device-Detected Atrial High-Rate Episodes in Patients Treated With Cardiac Resynchronization Therapy. Journal of Computer Assisted Tomography, 2020, 44, 784-789.	0.9	2
169	Atrial fibrillation is a marker of increased mortality risk in nonischemic heart failure—Results from the DANISH trial. American Heart Journal, 2021, 232, 61-70.	2.7	2
170	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy – a call for action for referral and optimization of care. Europace, 2023, 25, .	1.7	2
171	Rate of permanent cardiac implantable electronic device infections after active fixation temporary transvenous pacing: A nationwide Danish cohort study. Heart Rhythm O2, 2022, 3, 50-56.	1.7	2
172	Recurrent atrial arrhythmia in a randomised controlled trial comparing contact force–guided and contact force–blinded ablation for typical atrial flutter. Journal of Interventional Cardiac Electrophysiology, 2022, , 1.	1.3	2
173	Diagnostic Yield of Genetic Testing in Young Patients With Atrioventricular Block of Unknown Cause. Journal of the American Heart Association, 2022, 11, e025643.	3.7	2
174	Cardiac surgery in patients with cardiac implantable electronic devices and risk of device infections: a nationwide nested case–control study. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 897-904.	1.3	2
175	Need for real-world data on management of the (potentially) failing lead. Europace, 2014, 16, 1105-1106.	1.7	1
176	Can progression to permanent atrial fibrillation be prevented by pacing?: Figure 1. European Heart Journal, 2014, 35, 2349-2351.	2.2	1
177	Two Cases of Ventricular Proarrhythmia from Automatic Threshold Measurement Features in a CRTD and an ICD. , 2015, 20, 604-608.		1
178	Left ventricular performance during triggered left ventricular pacing in patients with cardiac resynchronization therapy and left bundle branch block. Journal of Interventional Cardiac Electrophysiology, 2016, 46, 345-351.	1.3	1
179	Validation of defibrillator lead performance registry data: insight from the Danish Pacemaker and ICD Register. Europace, 2017, 19, euw226.	1.7	1
180	Survey on the research activities within the EHRA Young EP community. Europace, 2019, 21, 670-672.	1.7	1

#	Article	IF	CITATIONS
181	Reproducibility and repeatability of identifying the latest electrical activation during mapping of coronary sinus branches in CRT recipients. Journal of Cardiovascular Electrophysiology, 2020, 31, 2940-2947.	1.7	1
182	The role of implantable cardioverter-defibrillators in asymptomatic patients with left ventricular dysfunction. European Heart Journal, 2020, 41, 2035-2035.	2.2	1
183	Reversible Complete Heart Block in a Pregnant Woman Related to Sertraline-Treatment. CJC Open, 2021, 4, 240-242.	1.5	1
184	EHRA/HRS/APHRS/LAHRS expert consensus on risk assessment in cardiac arrhythmias: Authors' reply. Europace, 2021, 23, 649-649.	1.7	1
185	Effect of implantable cardioverterâ€defibrillators in patients with nonâ€ischaemic systolic heart failure and concurrent coronary atherosclerosis. ESC Heart Failure, 2022, 9, 1287-1293.	3.1	1
186	Appropriate timing of electrophysiological study in myotonic dystrophy type 1: <i>unsolved question</i> —Authors' reply. Europace, 2021, , .	1.7	1
187	OUP accepted manuscript. Europace, 2022, , .	1.7	1
188	Lead complications after cardiac surgery in patients with cardiac implantable electronic devices. European Journal of Cardio-thoracic Surgery, 0, , .	1.4	1
189	New approach to implantable cardioverter-defibrillators in small pediatric patients: Dorsal positioning of superior vena cava shock lead in a 3-year-old. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 358-360.	0.8	0
190	Attitudes toward Catheter Ablation for Atrial Fibrillation: A Nationwide Survey among Danish Cardiologists. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1166-1172.	1.2	0
191	Guided left ventricular lead placement for cardiac resynchronization therapy – an opportunity for image integration: reply. European Journal of Heart Failure, 2017, 19, 1344-1344.	7.1	0
192	The time is not ripe for the wearable cardioverter-defibrillator. Europace, 2018, 20, f146-f147.	1.7	0
193	Risk Assessment in Cardiac Arrhythmias. European Heart Journal, 2020, 41, 4455-4457.	2.2	0
194	Is a ring of gold what we waited for to treat atrial fibrillation?. Europace, 2020, 22, 841-842.	1.7	0
195	Investigating sudden cardiac death – A new paradigm. Heart Rhythm O2, 2021, 2, 3-4.	1.7	0
196	CHA 2 DS 2 â€VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. European Journal of Clinical Investigation, 2021, , e13717.	3.4	0
197	2021 ESC guidelines on cardiac pacing and cardiac resynchronization: what is the correct level of evidence for the superiority of cephalic vein cutdown? C, B or maybe A?—Author's reply. Europace, 2022, , .	1.7	0
198	Cardiac computed tomography-verified right ventricular lead position and outcomes in cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology, 2022, , 1.	1.3	0

#	Article	IF	CITATIONS
199	Troubleshooting the difficult left ventricular lead placement in cardiac resynchronization therapy: current status and future perspectives. Expert Review of Medical Devices, 2022, 19, 341-352.	2.8	0